Ind-Swift Laboratories hit an upper circuit of 5% at Rs 21.65 after the company said its manufacturing facility at Derabassi in Punjab received establishment inspection report (EIR) from the US drug regulator.
The United States Food and Drug Administration (USFDA)'s inspection was conducted from 9 to 13 March 2020. The EIR has been issued without any FORM 483 observations.This is the sixth successful USFDA inspection completed by the company. Ind- Swift Supplies 15 APIs (Active Pharmaceutical Ingredients) to its customers based in the US. The APIs manufactured from the Derabassi facility are supplied to over 70 countries covering more than 280 customers including all the major drug manufacturers across the Globe, the company said in a statement.
Ind-Swift Laboratories manufactures bulk drugs and intermediates. The company's product portfolio includes anti-infective, anti-allergy, analgesic and cardiovascular medicines.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app